Should you consider BMAC or mFAT for knee OA?

For knee osteoarthritis, BMAC and microfragmented adipose tissue (mFAT, including Lipogems-type preparations) may be reasonable options in selected knees, but the present evidence does not show a clear routine advantage over PRP. PRP remains the best-established orthobiologic comparator, with a 2020 meta-analysis covering 34 randomised trials and showing partial symptomatic benefit over 6 to 12 months in some outcomes. By contrast, BMAC evidence suggests possible short- to mid-term pain and function improvement, while mFAT has encouraging small studies but a 2025 meta-analysis found no significant advantage over PRP, BMAC, hyaluronic acid or corticosteroid injection at 3, 6 or 12 months, with low-certainty evidence. The realistic aim is symptom relief and better function, not proven cartilage regrowth or a permanent fix. In knees with advanced structural damage, mainstream pathways still place arthroplasty as the established option rather than repeated biologic injections.

How are BMAC, mFAT and PRP different?

A practical way to separate these three knee injectables is to place them on a simple harvest spectrum before anything reaches the joint. PRP comes from peripheral blood, BMAC from bone marrow, and mFAT from fat obtained by lipoaspiration; all three are autologous, but they are biologically different products rather than interchangeable versions of the same thing. Lipogems is best viewed as a brand or processing system within the wider mFAT category, not a separate class of knee treatment in its own right.

• PRP usually starts with a blood draw and centrifugation, so the collection step is generally the simplest.
• BMAC requires bone marrow aspiration and then concentration of the aspirate, making the procedure more involved than PRP.
• mFAT requires fat harvest, often under local anaesthetic, followed by mechanical processing to remove oil and blood residue while preserving adipose tissue architecture.

Their intended role in knee OA is also different from surgery: these injections are usually framed as supporting the knee’s own repair signalling or anti-inflammatory response, not rebuilding a worn joint from scratch. Study comparison remains difficult because PRP and BMAC protocols, in particular, vary widely in harvest technique, processing and dose, so one clinic’s product may not be the same as another’s.

Why PRP is still the benchmark

In practice, PRP sets the comparison bar in knee osteoarthritis because it has the broadest clinical literature of the three options. A 2020 meta-analysis covering 34 randomised trials found that PRP outperformed placebo and several injectable comparators for some pain and function outcomes over roughly 6 to 12 months, and a 2021 randomised study of 150 patients reported better WOMAC, IKDC and walking-distance results than hyaluronic acid at 1 year. The important shift is to see PRP not as the automatic winner, but as the minimum evidence standard that newer orthobiologics have to beat.

That benchmark is still imperfect. PRP is not uniformly effective in every knee, and results may vary with osteoarthritis severity, formulation, dose and other patient factors; the 2021 trial itself stressed that preparation details matter. So the real question for BMAC or mFAT is not whether they sound more biologically sophisticated, but whether they can deliver clearly better or longer-lasting knee pain and function outcomes than a treatment that already has repeated randomised data behind it. At present, even that benchmark is heterogeneous, which is why careful protocol-level comparison matters.

What does the BMAC evidence actually show?

Put plainly, the clearest read of the knee osteoarthritis literature is that BMAC has supportive symptomatic data, mainly in the short to mid term. A 2024 narrative review described improvements in pain and function across published knee studies, and broader review material from 2022 points in the same direction. That is the useful part of the evidence: some patients report better knee pain and activity scores over the following months after injection.

The harder part is what the current evidence still has not shown. In the same 2024 review, long-term benefit and any consistent advantage over PRP were described as not firmly established. One reason is variation from study to study: marrow harvest technique, processing system, injectate volume, number of injections, and patient selection all differ, so “BMAC” in one paper may not match “BMAC” in another. The practical takeaway for knee care is therefore fairly simple: BMAC may be considered in selected cases when the extra marrow harvest and cost are thought justified, but it is not a proven upgrade from PRP. That caution also fits the regulatory backdrop: in its 22 July 2020 consumer alert, the FDA warned that regenerative products are often marketed with misleading claims, and most stem-cell products are not approved for orthopaedic uses such as knee OA.

What does mFAT or Lipogems show in knee OA?

The mFAT literature is best read as supportive but not decisive for knee osteoarthritis. A 2023 systematic review and meta-analysis reported that MFAT may improve knee symptoms, and a 2025 longitudinal study of 39 evaluable patients found clinically meaningful KOOS improvement through 12 months after a single injection, with no severe adverse events and minor self-limiting synovitis in 18%. That gives mFAT a real symptomatic signal in the knee, centred on pain and function rather than any proven structural reversal.

Where mFAT differs from a stronger comparator is in the comparative evidence. A 2025 meta-analysis of five studies found no statistically significant difference between MFAT and other injectables, including PRP and BMAC, at 3, 6 or 12 months, and rated the certainty as low. So the practical place for mFAT is not as a proven upgrade, but as one autologous, adipose-derived option that some clinicians may consider for selected knees. For Lipogems, the evidence in this packet is stronger for the broader mFAT category than for brand-specific claims, so any advantage should be framed cautiously.

Who may be a reasonable candidate and who should be cautious?

A more concrete way to judge candidacy is this: the most reasonable knee-OA candidate in 2025 is someone still limited by stairs, walking or sit-to-stand after the standard first-line package set out in the 2019 OARSI guideline and the 2020 JAMA review — education, structured land-based exercise, weight management, and analgesia or NSAIDs where appropriate, sometimes with selected injections already discussed.

For BMAC or mFAT, the strongest practical fit is therefore a patient seeking symptom relief, willing to undergo an autologous harvest procedure, and comfortable with some uncertainty. Published knee studies are still too heterogeneous to support precise matching claims by age, BMI, alignment, compartment, or radiographic grade; even 2025 MFAT cohorts spanning Kellgren-Lawrence II-IV do not tell us with confidence who the single “best responder” is.

Caution is sensible when clinics promise a “stem-cell cure”, definite “cartilage regrowth”, or a bespoke responder algorithm that current knee evidence does not support. It is also sensible when the knee is already in the territory of marked deformity, severe structural loss, or end-stage OA: in that setting, the 2020 JAMA review still places knee replacement on the standard pathway, so a biologic injection may be tried for symptoms in some cases but may be less likely to change the overall direction of care.

1. [1] Bone Marrow Aspirate Concentrate (BMAC) for Knee Osteoarthritis: A Narrative Review of Clinical Efficacy and Future Directions. (2025). https://doi.org/10.3390/medicina61050853 https://doi.org/10.3390/medicina61050853